[go: up one dir, main page]

AU6972798A - Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog - Google Patents

Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Info

Publication number
AU6972798A
AU6972798A AU69727/98A AU6972798A AU6972798A AU 6972798 A AU6972798 A AU 6972798A AU 69727/98 A AU69727/98 A AU 69727/98A AU 6972798 A AU6972798 A AU 6972798A AU 6972798 A AU6972798 A AU 6972798A
Authority
AU
Australia
Prior art keywords
hiv
replication
inhibition
binding domain
peptide analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69727/98A
Inventor
Michael J. Leibowitz
Arnold B Rabson
Stanley Stein
Jihong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of AU6972798A publication Critical patent/AU6972798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU69727/98A 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog Abandoned AU6972798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84444897A 1997-04-18 1997-04-18
US08844448 1997-04-18
PCT/US1998/007533 WO1998047913A2 (en) 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Publications (1)

Publication Number Publication Date
AU6972798A true AU6972798A (en) 1998-11-13

Family

ID=25292742

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69727/98A Abandoned AU6972798A (en) 1997-04-18 1998-04-16 Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog

Country Status (2)

Country Link
AU (1) AU6972798A (en)
WO (1) WO1998047913A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009056A1 (en) * 1997-08-19 1999-02-25 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030181367A1 (en) * 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
CA2386231C (en) * 1999-09-27 2010-09-14 Daniel J. O'mahony Membrane translocating peptide drug delivery system
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
ES2293977T3 (en) * 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHOD FOR USE.
WO2002062396A2 (en) * 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US7635681B2 (en) 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7364842B2 (en) 2003-05-19 2008-04-29 Irm, Llc Methods of identifying modulators of human retrovirus replication
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
IT1397569B1 (en) 2009-12-10 2013-01-16 Icgeb PEPTIDES AND THEIR DERIVATIVES THAT INHIBIT THE EXTRACELLULAR RELEASE OF HIV-1 PROTEIN TAT AND THE REPLICATION OF HIV-1.
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
ES2558106T3 (en) 2010-07-30 2016-02-02 Curevac Ag Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (en) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc MODIFIED ISOLATED POLYNUCLEOTIDE AND PHARMACEUTICAL COMPOSITION
PL2791160T3 (en) 2011-12-16 2022-06-20 Modernatx, Inc. Modified mrna compositions
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
EP3013353B1 (en) 2013-06-26 2021-04-21 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN114477459B (en) * 2022-01-17 2023-02-07 哈尔滨工业大学 A method of reducing antibiotic resistance genes in farming wastewater

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI931801L (en) * 1990-10-24 1993-04-21 Allelix Biopharma PEPTIDE INHIBITORER AV HI VIRUS REPLICATION

Also Published As

Publication number Publication date
WO1998047913A2 (en) 1998-10-29
WO1998047913A3 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
AU6972798A (en) Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
HUP9801323A3 (en) Use of benzotiophene derivatives for producing pharmaceutical compositions a for inhibiting cell-cell adhesion
AU9553098A (en) Manufacture of lithographic printing forms
AU2002246570A1 (en) Inhibition of restenosis using a dna-coated stent
AU6614696A (en) Inhibition of gene expression
AU6614596A (en) Inhibition of gene expression
AU2002229093A1 (en) Artificial tear composition containing a combination of three demulcents
AU1426295A (en) A potty
AU8912698A (en) Inhibition of hiv-1 replication using d-amino acid peptides
AU4663297A (en) Inhibition of hiv replication using soluble tat peptide analogs
AU7807098A (en) Inhibition of hiv replication using a mutated transfer rna primer
AU4248297A (en) Inhibition of viral replication
AU1750497A (en) Compounds capable of inhibiting hiv-1 infection
AU1703799A (en) Cyclooxygenase-2 inhibition
AU6522599A (en) Use of a self-cleaving rna motif to modulate gene expression
AU7686896A (en) Ring interferometer configuration for writing gratings
BR9611838A (en) Compounds useful for inhibiting replication of HIV-1 AND HIV-1 mutants
AU7212694A (en) Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
AU2088399A (en) Brefeldin a derivatives
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
AU8400698A (en) Improved dissolution inhibition resists for microlithography
AU6962894A (en) Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU1327997A (en) Illuminated digital/analog wristwatch
AU2095499A (en) Austenitic stainless steel including columbium
AUPN475295A0 (en) A toilet bowl

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase